A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Efgartigimod SC is the first-approved FcRn blocker globally and is marketed as VYVGART® Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and chronic ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Background Chronic inflammatory demyelinating neuropathy (CIDP) is the most common autoimmune neuropathy. 70-80% improve with first-line treatment, including IVIg. But 16-55% of patients enter ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Alnylam reports interim phase 1 data of nucresiran showing rapid knockdown of TTR that is sustained at six months following a single dose: Cambridge, Massachusetts Tuesday, Novemb ...

淀粉样蛋白是一类在人体内极易发生错误折叠并形成不可溶性纤维的蛋白质。当这些蛋白质在组织中堆积时，会对器官功能造成严重损害，进而引发疾病。迄今为止，研究人员已确认了36种易于形成淀粉样纤维的“淀粉样变”蛋白（amyloidogenic proteins ...